-Reuters
SVB Leerink Upgrades Moderna to Market Perform, Raises Price Target to $101
SVB Leerink analyst Mani Foroohar upgrades Moderna (NASDAQ:MRNA) from Underperform to Market Perform and raises the price target from $74 to $101.
Walmart Says On October 17 Will Begin Offering Over-The-Counter (OTC) Hearing Aids
-Reuters
Related Posts
Hall of Fame Resort & Entertainment Company Secures Approval For Sports Betting Licenses
Hall of Fame Village BetRivers Sportsbook location will be the only physical sports book in Stark County
Partnership with Betr will offer the first direct to consumer (DTC) platform solely dedicated to sports
Industry Comparison: Evaluating Adobe Against Competitors In Software Industry
In today’s rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to…
HSBC Downgrades Mosaic to Reduce, Lowers Price Target to $43
HSBC analyst Santhosh Seshadri downgrades Mosaic (NYSE:MOS) from Hold to Reduce and lowers the price target from $45 to $43.